SCHEMBL10312201

SCHEMBL10312201

Cc1cc(Nc2nc(/C=C/c3cccc(F)c3)nc(NCCCN3CCOCC3)n2)n[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 10/20 0.46
GRK6 P43250 1/20 0.45
GSK3A P49840 2/20 0.44
GSK3B P49841 2/20 0.44
POLB P06746 1/20 0.44
AURKA O14965 5/20 0.43
RET P07949 3/20 0.42
PLK4 O00444 4/20 0.42
NTRK1 P04629 4/20 0.42
AURKB Q96GD4 3/20 0.42
ABL1 P00519 2/20 0.42
LCK P06239 2/20 0.42
CSF1R P07333 2/20 0.42
KIT P10721 2/20 0.42
FGFR1 P11362 2/20 0.42
SRC P12931 2/20 0.42
PDGFRA P16234 2/20 0.42
TYK2 P29597 2/20 0.42
KDR P35968 2/20 0.42
PTK2 Q05397 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10312199 0.91 FLT3 (0.45) FLT3GRK6GSK3AGSK3BPOLB
SCHEMBL10312118 0.91 FLT3 (0.46) FLT3GRK6GSK3AGSK3BAURKA
SCHEMBL10312176 0.90 MELK (0.46) FLT3GRK6GSK3AGSK3BPOLB
SCHEMBL10312084 0.88 NTRK1 (0.46) FLT3GRK6GSK3AGSK3BPOLB
SCHEMBL10312188 0.85 JAK2 (0.41) FLT3GSK3AGSK3BAURKARET
SCHEMBL10312220 0.82 NTRK1 (0.50) FLT3GSK3AGSK3BPOLBAURKA
SCHEMBL10312150 0.82 IGF1R (0.48) FLT3NTRK1IGF1R
SCHEMBL10312149 0.81 FLT3 (0.45) FLT3GRK6GSK3AGSK3BFGFR1
SCHEMBL10312123 0.81 MELK (0.45) FLT3GRK6POLBAURKAABL1
SCHEMBL16556920 0.79 IGF1R (0.46) FLT3NTRK1IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178758-A1 STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS CALIFORNIA CAPITAL EQUITY, LLC (US) 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178758-A1 STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS STK25, STK35, SGK2 FLT3 152/4885GRK6 101/4885GSK3A 315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.